Advent Takes a Majority of NZCR With Waterman and Physicians Rolling:

Advent International announced on August 20, 2026, a majority investment in New Zealand Clinical Research Group, marking the firm's continued expansion into Asia-Pacific clinical-services infrastructure. The deal grants Advent majority control of the dual-geography clinical-trials operator, which runs early- and late-stage trials under the NZCR, CMAX, Optimal, and Fusion brand portfolio and serves pharmaceutical sponsors, biotechnology firms, and contract research organizations across both markets.

The transaction structure preserves meaningful continuity: existing investor Waterman Capital, CEO Tony Moffatt, and physician shareholders will retain a significant minority stake and remain operationally involved. Advent stated it will partner with the incumbent management team to expand NZCR's capabilities, sponsor relationships, and international footprint. The close is targeted for the fourth quarter 2026 and remains subject to regulatory approval in both jurisdictions.

Advent's healthcare track record provides context for the strategic fit. The firm has completed more than 55 healthcare investments across 17 countries over three decades and has committed more than $4 billion to nine pharma-services companies in the past ten years, including prior investments in Cohance, Simtra, and Felix Pharma. The NZCR investment reflects Advent's systematic approach to building scale in clinical-services verticals.

Deal consideration has not been disclosed. The Australian Financial Review reported a $1 billion valuation in its Street Talk column, but this figure remains single-sourced and unconfirmed by Advent or NZCR. Until official announcement of pricing or equity value, allocators should treat the transaction as a signed majority acquisition with a retained minority stake rather than a completed take-private or a priced transaction. The regulatory close remains the material gate for the 2026 fourth quarter.